JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75

Futu NewsDec 21 06:32 · Ratings

Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals

TipRanksDec 21 05:35 · Ratings

Rhythm Gets FDA Approval for Imcivree for Toddlers

Seeking AlphaDec 21 05:01

FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children

WSJDec 21 04:20

Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings

Seeking AlphaDec 21 04:00

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

BenzingaDec 21 03:24